Urogen Pharma
URGN41.0901.58% ( +0.640 )
Urogen Pharma (URGN)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel...
- Open
- 40.320
- High
- 41.605
- Low
- 40.320
- Prev. Close
- 40.450
- Volume
- 778.78K
- Turnover
- 32.03M
- Avg Price
- 41.124
- Bid/Ask Ratio
- --
- Amplitude
- 3.18%
- 52wk High
- 43.930
- Volume Ratio
- 1.04
- Turnover Ratio
- 1.80%
Urogen Pharma Analyst Rating
View MoreForecast & Rating
Jul 21, 2026Price forecast
$44.758.91%
Forecast & RatingStrong buy
8analysts
- Strong buy75.00%
- Buy12.50%
- Hold12.50%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · 1 day ago, 01:14 AM
Urogen Pharma (NASDAQ:URGN) Receives Average Rating of "Moderate Buy" from Analysts
- Tip Ranks · Jul 21 at 01:58 PM
Analyst Sees Strong Zusduri Upside, Lifts UroGen Pharma Price Target from $35 to $50 with Buy Rating
- Simplywall · Jul 21 at 12:04 AM
What UroGen Pharma (URGN)'s UGN-501 IND Clearance Means For Shareholders
- Barchart Option · Jul 17 at 09:15 AM
Short Sellers Are Betting Against UroGen Pharma Stock, But Wall Street Expects 263% Earnings Growth in 2027
- PUBT · Jul 15 at 07:02 AM
UroGen says USPTO allows new patent claims for ZUSDURI, UGN-103 through July 2044
- PUBT · Jul 10 at 01:18 PM
UroGen Pharma CMO Mark Schoenberg sells 10,000 shares for $400,100
